Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers

Journal of Human Hypertension

Volumn 11, Issue SUPPL. 2, 1997, Pages

  Hubner R ^a   Hogemann A M ^a   Sunzel, M ^b   Riddell, J G ^c  

^a Takeda Pharma GmbH   (Germany)

^b ASTRAZENECA R AND D   (Sweden)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Angiotensin II AT1 receptor blocker; Candesartan; Candesartan cilexetil; Elderly volunteers; Pharmacokinetics; Young volunteers

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I; CANDESARTAN HEXETIL; CV 15959; DIPEPTIDYL CARBOXYPEPTIDASE; HORMONE; RENIN; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG SAFETY; ELECTROCARDIOGRAPHY; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL ABSORPTION; HEADACHE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; META ANALYSIS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; AGE FACTORS; AGED; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0030667427     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Ogihara T, Higashimori K, Masuo K, Mikami H. Pilot study of a new angiotensin II receptor antagonist, TCV-116: effects of a single oral dose on blood pressure in patients with essential hypertension. Clin Ther 1993; 15(4): 684-691.
2. Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Heart J 1994; 127(5): 1388-1401.
3. Timmermans PB, Wong PC, Chiu AT, Herblin WF. Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sci 1991; 12(2): 55-62.
4. Wong PC et al. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2). J Pharmacol Exp Ther 1990; 255(2): 584-592.
5. Steinberg MI, Wiest SA, Palkowitz AD. Nonpeptide angiotensin II receptor antagonists. Cardiovasc Drug Rev 1993, 11(3): 312-358.
6. Waeber B, Brunner HR. Angiotensin II antagonists: A new class of antihypertensive agent. Br J Clin Pract 1996; 50(5): 265-268.
7. Israili Z, Hall WD. Cough and angioneurotic edema associated with angiotensin converting enzyme inhibitor therapy: A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-242.
8. Kubo K et al. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. J Med Chem 1993; 36(16): 2343-2349.
9. Morimoto S, Ogihara T. TCV-116: A new angiotensin II type-1 receptor antagonist. Cardiovasc Drug Rev 1994; 12(2): 153-164.
10. Delacretaz E et al. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995; 25(1): 14-21.
11. Lo M-L et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol & Ther 1995; 58(6): 641-649.
12. Criscone L et al. Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II anatagonist. Cardiovasc Drug Rev 1995; 13(3): 230-250.
13. nd edn. Applied Therapeutics Inc, Spokane WA, 1986, pp 229-293.